Practical aspects of the use of semaglutide (Ozempic®) in real clinical practice


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Type 2 diabetes mellitus (DM2) is one of the most common endocrine pathologies and has the greatest medico-social significance among all endocrine diseases. This is primarily due to high mortality and disability due to the development of cardiovascular diseases. The modern consensus approach to the DM2 treatment pays special attention to the use of hypoglycemic drugs with proven cardio- and nephroprotective properties. Among these drugs, it is necessary to distinguish a group of glucagon-like peptide-1 receptor agonists (GLP-1 RA). Semaglutidev is a new drug from this group; it has certain advantages over other members of the class. The article discusses the use of Semaglutide in the DM2 treatment.

Full Text

Restricted Access

About the authors

M. B Antsiferov

Endocrinological Dispensary of the Moscow Healthcare Department

Moscow, Russia

A. V Zilov

Sechenov University

Moscow, Russia

Olga M. Koteshkova

Endocrinological Dispensary of the Moscow Healthcare Department

Email: koala58@mail.ru
Cand. Sci. (Med.), Head of the Department of Diabetes Education and Treatment 37 Prechistenka St., Moscow 119034, Russian Federation

N. A Demidov

Hospital in Moskovsky town of the Moscow Healthcare Department

Moscow, Russia

References

  1. Анциферов М.Б, Демидов Н.А., Калашникова М.В. и др. Динамика основных эпидемиологических показателей у пациентов с сахарным диабетом, проживающих в Москве (2013-2018). Сахарный диабет. 2020;23(2):113-24. doi: 10.14341/DM11374.
  2. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й выпуск (дополненный). М., 2019. doi: 10.14341/DM221S1.
  3. Standards of Medical Care in Diabetes-2021. Diab Care. 2021;44(1):S1-2. Doi. 10.2337/dc21-Sint.
  4. Giaccari A., Solini A., Frontoni S., Del Prato S. Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism? Diab Care. 2021;44(3):647-54. Doi. 10.2337/ dc20-1964.
  5. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-12. doi: 10.1001/jama.281.21.2005.
  6. CAPTURE: a cross-sectional study of the contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes across 13 countries. URL: https://www.easd.org/virtualmeeting/home.html#!resources/capture-a-cross-sectional-study-of-the-contemporary-2019-prevalence-of-cardiovascular-disease-in-adults-with-type-2-diabetes-across-13-countries-6443597c-6a85-4a9e-8895-8e97f8f0c390.
  7. Garber A.J., Abrahamson M.J., Barzilay J.I., et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr. Pract. 2015;21:438-47. doi: 10.4158/EP15693.CS.
  8. Desouza C., Kirk A.R., Mangla K.K. et al. Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs). BMJ. Open Diab Res. Care. 2020;8:e001830. doi: 10.1136/bmjdrc-2020-001830.
  9. American Diabetes Association. 8. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes-2020. Diab Care. 2020;43:S89-97.
  10. Gorgojo-Martinez J.J., Gargallo-Fernández M.A., Brito-Sanfiel M., Lisbona-Catalán A. Real-world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: The CIBELES project. Int J Clin Pract. 2018;72(3): e13055. doi: 10.1111/ijcp.13055.
  11. Aroda V.R. A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. Diab Obes Metab. 2018;20(1):22-33. doi: 10.1111/dom.13162.
  12. Holst J.J. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-39.
  13. Bastien-Dionne P., Valenti L., Kon N., et al. Glucagon-like peptide 1 inhibits the sirtuin deacetylase SirT1 to stimulate pancreatic β-cell mass expansion. Diabetologia. 2011;60(12):3217-22. doi: 10.2337/db11-0101.
  14. Bagger J.I., Knop F.K., Lund А., et al. Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:737-45. doi: 10.1210/jc.2010-2435.
  15. Seghieri M., Rebelos E., Gastaldelli A., et al. Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia. 2013;56(1):156-61. doi: 10.1007/s00125-012-2738-3.
  16. Villanueva-Peňacarrillo M.L., Martfn-Duce A., Ramos-Âlvarez I., et al. Characteristic of GLP-1 effects on glucose metabolism in human skeletal muscle from obese patients. Regul Pept. 2011;168(1-3):39-44. doi: 10.1016/j.regpep.2011.03.002.
  17. Hayes M.R., Leichner T.M., Zhao S., et al. Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation. Cell Metab. 2011;13(3):320-30. doi: 10.1016/j.cmet.2011.02.001.
  18. De Heer J., Rasmussen C., Coy D.H., Holst J.J. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia. 2008;51:2263-70. doi: 10.1007/s00125-008-1149-y.
  19. Aldiss P., Davies G., Woods R., et al. 'Browning' the cardiac and peri-vascular adipose tissues to modulate cardiovascular risk. Int J Cardiol. 2017;228:265-74. doi: 10.1016/j.ijcard.2016.11.074.
  20. Marso S.P., Bain S.C., Consoli A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-44. doi: 10.1056/NEJMoa1607141.
  21. Marso S.P., Daniels G.H., Brown-Frandsen K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22. doi: 10.1056/NEJMoa1603827.
  22. Watts G.F., Chan D.C. Novel insights into the regulation of postprandial lipemia by glucagonlike peptides: significance for diabetes. Diabetologia. 2013;62(2):336-38. doi: 10.2337/db12-1098.
  23. Trujillo J.M., Nuffer J.W., Ellis S.L. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6(1):19-28. doi: 10.1177/2042018814559725.
  24. Sorli C., Sichi H., Tsoukas G.M., et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled,parallel-group, multinational, multicentre phase 3a trial. Lancet. Diab Endocrinol. 2017;5:251-60. Doi. 10.1016/S2213-8587 (17)30013-X.
  25. Ahrén B., Masmiquel L., Kumar H., et al. Efficacy and safety of onceweekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, doubleblind, phase 3a, randomised trial. Lancet. Diab Endocrinol. 2017;5(5):341-54. Doi. 10.1016/ S2213-8587(17)30092-X.
  26. Ahmann A.J., Capehorn M., Charpentier G., et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-albe, randomized clinical trial. Diab Care. 2017;43(7):1-9. Doi. 10.2337/dc17-0417/-/DC1.
  27. Aroda V.R., Bain S.C., Cariou B., et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallelgroup, multicenter. Mul Lancet. Diab Endocrinol. 2017;5(5):355-66. Doi. 10.1016/S2213-8587(17)30085-2.
  28. Rodbard H.W., Lingvay I., Reed J., et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291-301. Doi. 10.1210/jc.2018-00070.
  29. Pratley R.E., Aroda V.R., Lingvay I., et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet. Diab Endocrinol. 2018;6:1-12. Doi. 10.1016/S2213-8587(18)30024-X.
  30. Lingvay I., Catarig A.-M., Frias J.P., et al. Efficacy and safety of onceweekly semaglutide versus daily canagliflozin as add-on to metformin BROWN ET AL. 2019 in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet. Diab Endocrinol. 2019;7(11):834-44. Doi. 10.1016/ S2213-8587(19)30311-0.
  31. Capehorn M.S., Catarig A.-M., Furberg J.K., et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1,2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diab Metab. 2020;46(2):100-9. Doi. 10.1016/j.diabet.2019.101117.
  32. Lingvay I., Kirk A.R, Lophaven S., et al. 954-P: GLP-1 - Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting (EXPERT Study). Diabetologia. 2020. Doi. 10.2337/db20-954-P
  33. Brown R.E., Bech P.G., Aronson R. Semaglutide once weekly in people with type 2 diabetes: Realworld analysis of the Canadian LMC diabetes registry (SPARE study). Diab Obes Metab. 2020;22:2013-20. Doi. 10.1111/dom.14117.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies